Innovating Works

ReSOLUTE

Financiado
Research empowerment on solute carriers ReSOLUTE
The Research empowerment on solute carriers (ReSOLUTE) proposal aims at inducing a decisive acceleration in the intensity of SLC research worldwide while establishing solute carriers (SLCs) as a tractable target class. It is compo... The Research empowerment on solute carriers (ReSOLUTE) proposal aims at inducing a decisive acceleration in the intensity of SLC research worldwide while establishing solute carriers (SLCs) as a tractable target class. It is composed of a core consortium of seven academic/SME members (CeMM, Univ. of Oxford, Univ. of Manchester, AXXAM Spa, Univ. Leiden, Max-Planck Institut für medizinische Forschung, Univ. Wien) and six industrial partners (Pfizer Limited UK, Novartis Pharma AG, Boehringer-Ingelheim, Vifor Pharma Group, Sanofi Aventis Recherche et Développement, Bayer AG) with established and complementary expertise combining industry grade standards and systems level principle-driven analysis. ReSOLUTE merges systematic and focused approaches: 1) the generation of reliable and validated ‘hardware’ such as cell lines, proteins, antibodies/high affinity binders and large ‘omics’ datasets, 2) a central deorphanisation process coupling genomic engineering to metabolomics and supported by genetic and proteomics studies, 3) a non-redundant process to test systematically the suitability of a certain SLC to a variety of assay formats, 4) a collection of interlinked networks that cover different expertise, datasets and functional connections among SLCs, integrated into large-scale data repositories and a dedicated knowledgebase. The ReSOLUTE strategy will be applied in parallel at the super-family level and, in a more in-depth manner, to a prioritized gene list elected to be potential drug targets. To implement this and achieve the expected goals, the consortium is supported by a large network of academic and industrial partners with specific knowledge of certain SLCs and tools, willing to be accessed at any time and provide specific expertise. Together with a strong dissemination and exploitation plan, we therefore expect that ReSOLUTE will transform the landscape of SLC research for years to come. ver más
31/12/2023
CEMM FORSCHUNGSZE...
24M€
Duración del proyecto: 66 meses Fecha Inicio: 2018-06-22
Fecha Fin: 2023-12-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2023-12-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
IMI2-2016-10-06: Unlocking the Solute Carrier Gene-Family for Effective New Therapies (Unlock SLCs)
Cerrada hace 7 años
Presupuesto El presupuesto total del proyecto asciende a 24M€
Líder del proyecto
CEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZ... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5